Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
EBioMedicine ; 44: 516-529, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31130472

RESUMEN

BACKGROUND: Zika virus (ZIKV) infection during pregnancy may cause major congenital defects, including microcephaly, ocular, articular and muscle abnormalities, which are collectively defined as Congenital Zika Syndrome. Here, we performed an in-depth characterization of the effects of congenital ZIKV infection (CZI) in immunocompetent mice. METHODS: Pregnant dams were inoculated with ZIKV on embryonic day 5.5 in the presence or absence of a sub-neutralizing dose of a pan-flavivirus monoclonal antibody (4G2) to evaluate the potential role of antibody-dependent enhancement phenomenon (ADE) during short and long outcomes of CZI. FINDINGS: ZIKV infection induced maternal immune activation (MIA), which was associated with occurrence of foetal abnormalities and death. Therapeutic administration of AH-D antiviral peptide during the early stages of pregnancy prevented ZIKV replication and death of offspring. In the post-natal period, CZI was associated with a decrease in whole brain volume, ophthalmologic abnormalities, changes in testicular morphology, and disruption in bone microarchitecture. Some alterations were enhanced in the presence of 4G2 antibody. INTERPRETATION: Our results reveal that early maternal ZIKV infection causes several birth defects in immunocompetent mice, which can be potentiated by ADE phenomenon and are associated with MIA. Additionally, antiviral treatment with AH-D peptide may be beneficial during early maternal ZIKV infection. FUND: This work was supported by the Brazilian National Science Council (CNPq, Brazil), Minas Gerais Foundation for Science (FAPEMIG), Funding Authority for Studies and Projects (FINEP), Coordination of Superior Level Staff Improvement (CAPES), National Research Foundation of Singapore and Centre for Precision Biology at Nanyang Technological University.


Asunto(s)
Acrecentamiento Dependiente de Anticuerpo/inmunología , Interacciones Huésped-Patógeno/inmunología , Complicaciones Infecciosas del Embarazo , Infección por el Virus Zika/inmunología , Infección por el Virus Zika/virología , Virus Zika/fisiología , Animales , Anticuerpos Antivirales/inmunología , Antivirales/farmacología , Huesos/diagnóstico por imagen , Huesos/patología , Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Encéfalo/patología , Encéfalo/virología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Femenino , Humanos , Ratones , Péptidos/farmacología , Embarazo , Bazo/efectos de los fármacos , Bazo/inmunología , Bazo/patología , Bazo/virología , Síndrome , Resultado del Tratamiento , Carga Viral , Infección por el Virus Zika/diagnóstico , Infección por el Virus Zika/tratamiento farmacológico
2.
Med Chem ; 15(1): 38-50, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30058497

RESUMEN

BACKGROUND: Microbial infections is a global public health problem. The aim of this work was to synthesize and evaluate the antimicrobial activity of novel triazoles, morpholines and thiosemicarbazones. METHODS: Compounds were synthesized using 2,4-Dihydroxyacetophenone and 4-hydroxybenzaldehyde as starting materials. The antimicrobial activity of these compounds against bacteria and yeast was evaluated by the broth microdilution method. RESULTS: The proposed route for synthesis gave high to moderate yields, moreover these compounds were successfully characterized by 1H NMR, 13C NMR and LC-MS. Antimicrobial testing indicated that the thiosemicarbazone and morphine derivatives had the best antimicrobial activity against the microorganisms tested with minimum inhibitory concentrations (MIC) between 0.29 and 5.30 µM. Thiosemicarbazone derivative (12) was able to inhibit the growth of C. tropicalis, with minimum fungicidal concentration (MFC) of 0.55 µM. In addition, this compound was active against E. coli, S. aureus and S. epidermidis, with MIC values ranging from 0.29 to 1.11 µM. Moreover, the morpholine derivative (15) had an MIC value of 0.83 µM against C. albicans and E. coli. CONCLUSION: We have efficiently synthesized a series of eleven novel triazoles, thiosemicarbazones and morpholine derivatives using 2,4-Dihydroxyacetophenone and 4-hydroxybenzaldehyde as starting materials. Thiosemicarbazone derivative (12) showed promising antifungal and antibacterial activity and these findings suggest that this compound can be used as scaffolds to design new antimicrobial drugs.


Asunto(s)
Antibacterianos/farmacología , Antifúngicos/farmacología , Morfolinas/farmacología , Tiosemicarbazonas/farmacología , Triazoles/farmacología , Acetofenonas/síntesis química , Acetofenonas/farmacología , Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/síntesis química , Antifúngicos/síntesis química , Candida/efectos de los fármacos , Chalconas/síntesis química , Chalconas/farmacología , Escherichia coli/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Morfolinas/síntesis química , Staphylococcus aureus/efectos de los fármacos , Staphylococcus epidermidis/efectos de los fármacos , Tiosemicarbazonas/síntesis química , Triazoles/síntesis química
3.
J Antibiot (Tokyo) ; 71(8): 702-712, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29674635

RESUMEN

Vulvovaginal candidiasis (VVC) affects millions of women around the world every year. Candida albicans is the most frequently isolated pathogen in women and its rapid ability to develop resistance to first and second line therapies has boosted the search for new and effective antifungal agents. In this study, we show the in vitro anti-Candida activity of fifteen synthetic chalcone analogs and their antifungal potential in an in vivo model of VVC. Chalcone 12 showed potent antifungal effects, being able to inhibit the growth of Candida spp. at a concentration of 15.6 µg mL-1. In addition, mechanism of action studies have indicated the ergosterol fungal membrane as the target of this compound. Despite a considerable antifungal activity, the chalcone 12 showed high cytotoxicity in kidney cells lineages. Moreover, this compound was able to reduce Candida-associated virulence, impairing yeast-hyphal transition in C. albicans. An in vivo model of VVC showed that chalcone 12 significantly reduces the fungal load. Taken together, these findings showed that the chalcone 12 is a potent anti-Candida agent in vitro beyond of contribute to improve the fungal infection in a model of CVV. However, it showed low selectivity and high toxicity, suggesting molecular modifications to minimize these proprieties.


Asunto(s)
Antifúngicos/farmacología , Candida albicans/efectos de los fármacos , Candidiasis Vulvovaginal/tratamiento farmacológico , Chalconas/síntesis química , Chalconas/farmacología , Diseño de Fármacos , Animales , Antifúngicos/síntesis química , Candida albicans/aislamiento & purificación , Línea Celular , Chlorocebus aethiops , Cricetinae , Femenino , Humanos , Pruebas de Sensibilidad Microbiana , Ratas , Ratas Wistar , Relación Estructura-Actividad , Células Vero
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA